急诊胸痛伴肌钙蛋白升高患者的诊断、治疗与结局的性别差异
该研究纳入加拿大温哥华两家医院2008年5月至2013年3月因缺血性胸痛就诊并检测肌钙蛋白的7272例成人(女性2933例,男性4339例)。在胸痛呈心脏特征且cTn>99百分位时,女性心梗诊断率46.4%低于男性57.5%;女性cTnI>99百分位组1年MACE率22.7%(95%CI 18.5-27.7),男性为18.8%(95%CI 16.2-21.6),校正基线差异后差异减弱且无统计学显著性。7天内诊断性导管检查女性48.4%低于男性64.3%(p<0.001),90天内女性循证心脏药物使用较少,男性他汀处方填充比女性多25%。结论认为性别差异不能由胸痛特征或cTn水平解释,较高MACE率似乎由合并症负担更高驱动。
要点
- 胸痛呈心脏特征且cTn>99百分位时,女性心梗诊断率46.4%低于男性57.5%。
- cTnI>99百分位组女性1年MACE率22.7%(95%CI 18.5-27.7),男性18.8%(95%CI 16.2-21.6),校正后差异无统计学显著性。
- cTn>99百分位且胸痛为心脏性时,7天内诊断性导管检查女性48.4%低于男性64.3%(p<0.001)。
- 90天内女性循证心脏药物使用较少,男性他汀处方填充比女性多25%,校正基线差异未减弱。
- 女性1年MACE率最高,但该差异似乎由合并症负担更高驱动,而非胸痛特征或cTn水平。
适用人群与场景
- 2008年5月至2013年3月就诊于加拿大温哥华两家医院急诊、因缺血性胸痛就诊并检测肌钙蛋白的全部成人。
研究设计与关键结果
- 研究类型为队列研究,纳入7272例患者(女性2933例,男性4339例),来自加拿大温哥华两家医院。
- 胸痛呈心脏特征/病史且cTn>99百分位时,女性心梗诊断率46.4%,男性57.5%。
- cTnI>99百分位组女性1年MACE率22.7%(95%CI 18.5-27.7),男性18.8%(95%CI 16.2-21.6),校正基线差异后差异减弱且无统计学显著性。
- cTn>99百分位且胸痛为心脏性时,7天内诊断性导管检查女性48.4%,男性64.3%(p<0.001)。
- 90天内女性循证心脏药物使用较少,男性他汀处方填充比女性多25%,校正基线差异未减弱。
证据类型、等级与局限
- 证据类型为队列研究,原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论提示,急诊胸痛伴cTn>99百分位的女性较少被诊断为心梗、较少在7天内接受诊断性导管检查、较少使用循证心脏药物,但1年MACE率最高,且较高MACE率似乎由合并症负担更高驱动。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: While sex differences in the treatment and outcomes of subjects with acute coronary syndromes are well documented, little is known about the impact of cardiac troponin (cTn) levels obtained in the emergency department (ED) on the observed sex differences. We sought to determine whether cTn levels by chest pain features modify sex differences in diagnosis, treatment, and outcomes in patients presenting with chest pain suggestive of ischemia.
METHODS: All adults presenting to two hospitals in Vancouver, Canada, between May 2008 and March 2013 with ischemic chest pain and with cTn testing were included in the study. Outcomes were obtained through data linkage with population-based administrative data sets, including Vital Statistics (death), Discharge Abstract Database (hospitalizations), and PharmaNet (medications). Cumulative event rates for the composite major adverse cardiac event (MACE) endpoint (death, myocardial infarction [MI], incident admission for heart failure or for angina requiring diagnostic catheterization or revascularization) were estimated for each sex and cTn level using the Kaplan-Meier method; Cox models were used to estimate hazard ratios and 95% confidence interval (CIs) for 1-year MACE and 7-day catheterization. Logistic models were used to estimate odds ratios (ORs) and 95% CI for 90-day medication use.
RESULTS: Over the 5-year study period, 25,539 patients presented to the ED with chest pain of which 7,272 (2,933 females and 4,339 males) met the inclusion criteria. Among patients with chest pain with cardiac features/history and cTn > 99th percentile, females were less likely to be diagnosed with MI (46.4% vs. 57.5%). Females in the cTnI > 99th percentile group had the worst outcomes with a 1-year MACE rate of 22.7% (95% CI = 18.5-27.7) versus 18.8% (95% CI = 16.2-21.6), although this difference was attenuated and not statistically significant after adjustment for baseline differences. Overall, females underwent fewer diagnostic catheterizations than males within 7 days of admission to the ED. Even when cTn was above the 99th percentile and the chest pain was cardiac in nature, 48.4% of females underwent a diagnostic catheterization compared to 64.3% of males (p < 0.001). Within 90 days of discharge, females were less likely to use the evidence-based cardiac medications. The most striking sex differences were noted when cTnI levels were > 99th percentile and when the chest pain was cardiac in nature; males filled 25% more prescriptions for statins than their female counterparts. Adjustment for baseline differences did not attenuate this difference.
CONCLUSIONS: Sex differences in diagnosis and treatment after presentation to the ED with chest pain are not explained by differences in chest pain features or levels of cTn. Even when females have cardiac chest pain and cTn levels > 99th percentile, they are less likely to be diagnosed with MI, less likely to undergo diagnostic cardiac catheterization within 7 days, and less likely to use evidence-based cardiac medications, but they have the highest 1-year MACE rate. The higher MACE rate appears to be driven by the higher burden of comorbid conditions.
参考来源
- Humphries KH, Lee MK, Izadnegahdar M, et al. Sex Differences in Diagnoses, Treatment, and Outcomes for Emergency Department Patients With Chest Pain and Elevated Cardiac Troponin. Acad Emerg Med. 2018. PMID: 29274187. doi:10.1111/acem.13371
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。